Clinical Research Directory
Browse clinical research sites, groups, and studies.
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
Sponsor: Bispebjerg Hospital
Summary
To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.
Official title: Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (DANBLOCK)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2760
Start Date
2018-12-17
Completion Date
2035-12-10
Last Updated
2025-06-10
Healthy Volunteers
No
Conditions
Interventions
Metoprolol Succinate
Eligible patients randomized to receive long-term therapy with oral beta-blockade
Bisoprolol
Eligible patients randomized to receive long-term therapy with oral beta-blockade
Carvedilol
Eligible patients randomized to receive long-term therapy with oral beta-blockade
Nebivolol
Eligible patients randomized to receive long-term therapy with oral beta-blockade
Locations (1)
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23
Copenhagen, Denmark